Unicycive Therapeutics, Inc. (UNCY)
3.585
-0.12
(-3.11%)
USD |
NASDAQ |
Oct 15, 16:00
3.65
+0.06
(+1.81%)
After-Hours: 20:00
Unicycive Therapeutics Shareholders Equity (Quarterly) : 53.27M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 53.27M |
| March 31, 2026 | 37.70M |
| December 31, 2025 | 30.20M |
| September 30, 2025 | 37.48M |
| June 30, 2025 | 16.43M |
| March 31, 2025 | 11.27M |
| December 31, 2024 | 7.431M |
| September 30, 2024 | 27.85M |
| June 30, 2024 | -14.85M |
| March 31, 2024 | -24.46M |
| December 31, 2023 | -3.809M |
| September 30, 2023 | 3.39M |
| June 30, 2023 | -19.37M |
| March 31, 2023 | -15.08M |
| Date | Value |
|---|---|
| December 31, 2022 | -0.466M |
| September 30, 2022 | 4.626M |
| June 30, 2022 | 9.91M |
| March 31, 2022 | 13.24M |
| December 31, 2021 | 16.48M |
| September 30, 2021 | 19.00M |
| June 30, 2021 | -4.202M |
| March 31, 2021 | -3.402M |
| December 31, 2020 | -2.671M |
| September 30, 2020 | -1.861M |
| June 30, 2020 | -1.303M |
| March 31, 2020 | |
| December 31, 2019 | -0.884M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 72.03M |
| Total Liabilities (Quarterly) | 18.76M |
| Debt to Equity Ratio | 0.0139 |
| Current Ratio | 3.813 |
| Net Debt Paydown Yield | -0.03% |